Nasdaq

Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU™ [Immune Globulin ...
Seeking Alpha

CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe

- Hizentra ® is the #1 immune globulin prescribed for Primary Immunodeficiency (PI) in the U.S. - Hizentra is the first and only subcutaneous immune globulin (SCIg) treatment approved for Chronic ...
Seeking Alpha

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the First and Only Facilitated Subcutaneous Immunoglobulin (fSCIG) Approved in Japan for Agammaglobulinemia and ...
Monthly Prescribing Reference

Subcutaneous Immune Globulin Hizentra Available in 10g Prefilled Syringe

“The availability of the 10g prefilled syringe is CSL Behring’s latest development in helping the rare disease community effectively manage PI and CIDP, as some patients may require treatment at a ...
Healio

C1 inhibitor prevents adverse events from immunoglobulin replacement therapy

Please provide your email address to receive an email when new articles are posted on . Immunoglobulin replacement therapy triggered severe neuropathy. A 4,200 U dose ...
Business Insider

Takeda Says Japan Approves CUVITRU Subcutaneous Immunoglobulin For Patients With Agammaglobulinemia

(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TAK) announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] ...
Medical News Today

Hizentra (immune globulin subcutaneous [human]) dosing schedule and details

The prescribed dosage for Hizentra (immune globulin subcutaneous [human]) may vary depending on an individual’s treatment plan. Other factors, including your specific diagnosis, body weight, and ...
FiercePharma

With Vyvgart 'firing' in myasthenia gravis, argenx lays launch plans for next potential autoimmune approval: CEO

Despite a pair of clinical misfires in 2023, argenx has stuck by the thesis that its star drug Vyvgart, also known as efgartigimod, can tackle a wide array of autoimmune diseases linked to ...
Cure Today

Switching to Subcutaneous Medication for My Cancer-Induced Compromised Immune System Was Life Changing

Once I got the hang of administering subcutaneous immunoglobulin, my life was so much easier, as I no longer had to undergo monthly IV infusions for my cancer-related compromised immune system. After ...
Healio

FDA approves Xembify for biweekly dosing, treatment-naïve patients

Please provide your email address to receive an email when new articles are posted on . The company expects Xembify’s expanded use to be available in the U.S. by the end of September. The expanded ...
Healthline

Ask the Expert: Infusions for Myasthenia Gravis

Neurologist Susan W. Lee, DO, answers common questions about this treatment option for myasthenia gravis. Intravenous immunoglobulin (IVIG) is a pooled collection of antibodies derived from donors’ ...